Australia's most trusted
source of pharma news
Thursday, 11 September 2025
Posted 11 September 2025 AM
Takeda is a step closer to launching a first-in-class orexin agonist drug for narcolepsy type 1 after revealing outstanding results from Phase 3 trials.
The Japanese company said it is on track to submit global regulatory applications this financial year for oveporexton, its oral orexin receptor 2 (OX2R)-selective agonist in narcolepsy type 1 (NT1), which could unlock what Wall Street analysts say could be a US$9 billion market.
Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.